A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive
A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive
The main purpose of this study is to evaluate the effectiveness and safety of ixekizumab versus adalimumab in participants with psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drugs (DMARD) naive.
Inclusion Criteria:
Exclusion Criteria:
Ciudad Autonoma de Buenos Aire, Buenos Aires C1426AAL, Argentina
Ciudad de Buenos Aires, Buenos Aires C1430EGF, Argentina
Ciudad Autonoma de Buenos Aire, C1015ABO, Argentina
Ciudad Autonoma de Buenos Aire, C1204AAD, Argentina
Ciudad Autonoma de Buenos Aire, C1221ADC, Argentina
Ciudad Autonoma de Buenos Aire, C1417EYG, Argentina
Ciudad Autonoma de Buenos Aire, C1440AAD, Argentina
Hyderabad, Andhra Pradesh 500035, India
Muckleneuk, 0135, South Africa